JP2023543038A5 - - Google Patents
Info
- Publication number
- JP2023543038A5 JP2023543038A5 JP2023519291A JP2023519291A JP2023543038A5 JP 2023543038 A5 JP2023543038 A5 JP 2023543038A5 JP 2023519291 A JP2023519291 A JP 2023519291A JP 2023519291 A JP2023519291 A JP 2023519291A JP 2023543038 A5 JP2023543038 A5 JP 2023543038A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- pharmaceutically acceptable
- acceptable salt
- hydrogen atom
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063084217P | 2020-09-28 | 2020-09-28 | |
| US63/084,217 | 2020-09-28 | ||
| PCT/US2021/052025 WO2022067082A1 (en) | 2020-09-28 | 2021-09-24 | Fused heteroaryl compounds and their use as camkii inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023543038A JP2023543038A (ja) | 2023-10-12 |
| JP2023543038A5 true JP2023543038A5 (enExample) | 2024-10-01 |
| JP7824282B2 JP7824282B2 (ja) | 2026-03-04 |
Family
ID=80821052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023519291A Active JP7824282B2 (ja) | 2020-09-28 | 2021-09-24 | 縮合ヘテロアリール化合物およびＣａＭＫＩＩ阻害剤としてのその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11795172B2 (enExample) |
| EP (1) | EP4216948A4 (enExample) |
| JP (1) | JP7824282B2 (enExample) |
| KR (1) | KR20230107551A (enExample) |
| CN (1) | CN116940354A (enExample) |
| AU (1) | AU2021350015A1 (enExample) |
| CA (1) | CA3196946A1 (enExample) |
| CL (1) | CL2023000894A1 (enExample) |
| CO (1) | CO2023005189A2 (enExample) |
| IL (1) | IL301480A (enExample) |
| MX (1) | MX2023003610A (enExample) |
| PE (1) | PE20240148A1 (enExample) |
| TW (1) | TW202229273A (enExample) |
| WO (1) | WO2022067082A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7824282B2 (ja) * | 2020-09-28 | 2026-03-04 | カーデュリオン・ファーマシューティカルズ・インコーポレイテッド | 縮合ヘテロアリール化合物およびＣａＭＫＩＩ阻害剤としてのその使用 |
| WO2023134692A1 (zh) * | 2022-01-13 | 2023-07-20 | 浙江同源康医药股份有限公司 | 多环类化合物及其用途 |
| CN115160235B (zh) * | 2022-08-10 | 2023-12-15 | 宜宾学院 | 一种2,3-二氢喹唑啉-4(1h)-酮类化合物及其超声合成方法 |
| US20250145630A1 (en) * | 2023-11-07 | 2025-05-08 | Cardurion Pharmaceuticals, Inc. | Polymorphs of a pyridinylimidazo[1,2-b]pyridazine |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1317266A2 (en) | 2000-08-08 | 2003-06-11 | Ortho-McNeil Pharmaceutical, Inc. | Neuroprotective 2-pyridinamine compositions and related methods |
| HK1054393B (en) | 2000-09-20 | 2009-08-28 | Ortho-Mcneil Pharmaceutical, Inc. | Pyrazine derivatives as modulators of tyrosine kinases |
| US20030187026A1 (en) * | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| JP2007504229A (ja) | 2003-09-02 | 2007-03-01 | メルク エンド カムパニー インコーポレーテッド | 代謝調節型グルタミン酸受容体−５のモジュレーターとしてのビピリジルアミン類およびエーテル類 |
| US7776857B2 (en) | 2007-04-05 | 2010-08-17 | Amgen Inc. | Aurora kinase modulators and method of use |
| US9216173B2 (en) | 2011-10-05 | 2015-12-22 | Merck Sharp & Dohme Corp. | 2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors |
| HRP20180037T1 (hr) | 2012-04-17 | 2018-03-23 | Fujifilm Corporation | Heterociklični spoj koji sadrži dušik ili njegovu sol |
| CA2894126A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| CN107074856A (zh) * | 2014-09-05 | 2017-08-18 | 阿略斯泰罗斯医疗公司 | CaMKII抑制剂及其用途 |
| AR110252A1 (es) | 2016-11-30 | 2019-03-13 | Gilead Sciences Inc | Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam |
| CN110799190B (zh) | 2017-03-27 | 2024-04-19 | 卡都瑞恩医药有限公司 | 杂环化合物 |
| JP7447098B2 (ja) | 2018-09-25 | 2024-03-11 | カーデュリオン・ファーマシューティカルズ・インコーポレイテッド | アミノピリミジン化合物 |
| WO2020068846A1 (en) * | 2018-09-25 | 2020-04-02 | Heterocyclic Compound | Heterocyclic compound |
| US20230000842A1 (en) | 2019-01-17 | 2023-01-05 | Samumed, Llc | Methods of treating cartilage disorders through inhibition of clk and dyrk |
| JP7824282B2 (ja) * | 2020-09-28 | 2026-03-04 | カーデュリオン・ファーマシューティカルズ・インコーポレイテッド | 縮合ヘテロアリール化合物およびＣａＭＫＩＩ阻害剤としてのその使用 |
-
2021
- 2021-09-24 JP JP2023519291A patent/JP7824282B2/ja active Active
- 2021-09-24 WO PCT/US2021/052025 patent/WO2022067082A1/en not_active Ceased
- 2021-09-24 EP EP21873547.0A patent/EP4216948A4/en active Pending
- 2021-09-24 CN CN202180079818.5A patent/CN116940354A/zh active Pending
- 2021-09-24 CA CA3196946A patent/CA3196946A1/en active Pending
- 2021-09-24 US US17/485,137 patent/US11795172B2/en active Active
- 2021-09-24 PE PE2023001229A patent/PE20240148A1/es unknown
- 2021-09-24 AU AU2021350015A patent/AU2021350015A1/en active Pending
- 2021-09-24 TW TW110135508A patent/TW202229273A/zh unknown
- 2021-09-24 KR KR1020237014351A patent/KR20230107551A/ko active Pending
- 2021-09-24 IL IL301480A patent/IL301480A/en unknown
- 2021-09-24 MX MX2023003610A patent/MX2023003610A/es unknown
-
2023
- 2023-03-28 CL CL2023000894A patent/CL2023000894A1/es unknown
- 2023-04-24 CO CONC2023/0005189A patent/CO2023005189A2/es unknown
- 2023-08-28 US US18/238,949 patent/US12528816B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023543038A5 (enExample) | ||
| US20230346927A1 (en) | COMBINATION of ATR KINASE INHIBITORS and PD-1/PD-L1 INHIBITORS | |
| JP6499749B2 (ja) | Ｒｏｃｋの阻害剤としてのスピロシクロヘプタン | |
| AU2014272776B2 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | |
| Martorana et al. | Heterocyclic scaffolds for the treatment of Alzheimer’s disease | |
| JP2013515070A5 (enExample) | ||
| JP2016164184A5 (enExample) | ||
| JP2018502900A (ja) | ジスコイジンドメイン受容体１を標的化する小分子阻害剤およびその使用 | |
| JP2013523884A5 (enExample) | ||
| JP2014532070A5 (enExample) | ||
| JP2012532112A5 (enExample) | ||
| HUE025162T2 (en) | THE USE OF sGC STIMULATORS, sGC ACTIVATORS, ALONE AND COMBINATIONS WITH PDE5 INHIBITORS FOR THE TREATMENT OF SYSTEMIC SCLEROSIS (SSc) | |
| JP2016519096A5 (enExample) | ||
| JP2013542253A (ja) | ｓＧＣ刺激剤 | |
| AU2007293885A1 (en) | Combination treatment for diabetes mellitus | |
| EP3585365B1 (en) | Combination of atr kinase inhibitors with parp inhibitors | |
| JP2008523041A5 (enExample) | ||
| US20210260036A1 (en) | Methods of treatment for alpha-1 antitrypsin deficiency | |
| WO2018153971A1 (en) | Combination of atr kinase inhibitors | |
| JP2021518379A5 (enExample) | ||
| JP2021514011A5 (enExample) | ||
| WO2018153969A1 (en) | Combination of atr kinase inhibitors with radium-223 salt | |
| WO2018153972A1 (en) | Combination of atr kinase inhibitors and antiandrogens | |
| KR20230040978A (ko) | 투렛 증후군의 치료를 위한 포스포디에스테라제 10 억제제의 용도 | |
| KR20010110793A (ko) | 혈관협착증 예방 및 치료제 |